These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37385959)

  • 1. Urinary α1 microglobulin level is useful for selecting sodium-glucose transporter 2 inhibitor or metformin for visceral fat reduction in patients with type 2 diabetes.
    Koshizaka M; Ishibashi R; Ishikawa K; Shoji M; Ide K; Ide S; Kato H; Teramoto N; Terayama R; Maezawa Y; Yokote K;
    Diabetes Obes Metab; 2023 Oct; 25(10):3071-3075. PubMed ID: 37385959
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the Impact of SGLT2-Inhibitors and Exenatide on Body Fat Composition.
    Agcakaya E; Mutlu HH; Erbakan A; Sargin M
    J Coll Physicians Surg Pak; 2023 Mar; 33(3):308-313. PubMed ID: 36945162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study).
    Koshizaka M; Ishikawa K; Ishikawa T; Kobayashi K; Takemoto M; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Tatsuno I; Terano T; Hashimoto N; Kuribayashi N; Uchida D; Yokote K;
    BMJ Open; 2017 May; 7(5):e015766. PubMed ID: 28490565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reduction.
    Tsukagoshi-Yamaguchi A; Koshizaka M; Ishibashi R; Ishikawa K; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Terayama R; Hattori A; Takemoto M; Ouchi Y; Maezawa Y; Yokote K;
    Pharmacotherapy; 2023 Dec; 43(12):1317-1326. PubMed ID: 37772313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes.
    Hao Z; Sun Y; Li G; Shen Y; Wen Y; Liu Y
    BMC Endocr Disord; 2022 Feb; 22(1):37. PubMed ID: 35144596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
    De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A
    Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment.
    Packer M
    Am J Med; 2020 Jul; 133(7):781-782. PubMed ID: 32061625
    [No Abstract]   [Full Text] [Related]  

  • 8. Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study.
    Sasaki T; Sugawara M; Fukuda M
    J Diabetes Investig; 2019 Jan; 10(1):108-117. PubMed ID: 29660782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.
    Li J; Gong Y; Li C; Lu Y; Liu Y; Shao Y
    Medicine (Baltimore); 2017 Jul; 96(27):e7201. PubMed ID: 28682870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
    Shestakova MV; Wilding JPH; Wilpshaar W; Tretter R; Orlova VL; Verbovoy AF
    Diabetes Res Clin Pract; 2018 Dec; 146():240-250. PubMed ID: 30391333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus.
    Molugulu N; Yee LS; Ye YT; Khee TC; Nie LZ; Yee NJ; Yee TK; Liang TC; Kesharwani P
    Diabetes Res Clin Pract; 2017 Oct; 132():157-168. PubMed ID: 28797524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom.
    Pawaskar M; Bilir SP; Kowal S; Gonzalez C; Rajpathak S; Davies G
    Diabetes Obes Metab; 2019 Apr; 21(4):1010-1017. PubMed ID: 30565386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes.
    Tosaki T; Kamiya H; Himeno T; Kato Y; Kondo M; Toyota K; Nishida T; Shiroma M; Tsubonaka K; Asai H; Moribe M; Nakaya Y; Nakamura J
    Intern Med; 2017; 56(6):597-604. PubMed ID: 28321056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
    Chen Z; Li G
    Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [DPP-4 or SGLT2 inhibitor added to metformin alone in type 2 diabetes].
    Paquot N; Scheen AJ
    Rev Med Suisse; 2017 Aug; 13(571):1410-1415. PubMed ID: 28837277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.
    Shin Y; Moon JH; Chin HJ; Ferrannini E; Lim S
    Endocrinol Metab (Seoul); 2020 Jun; 35(2):329-338. PubMed ID: 32615717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relative frequency of urinary tract infections in patients affected by diabetes mellitus type 2 treated with metformin and SGLT2 inhibitor.
    Merész G; Szabó S; Dóczy V; Hölgyesi Á; Szakács Z
    Orv Hetil; 2020 Mar; 161(13):491-501. PubMed ID: 32202151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.
    Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    Intern Med; 2018 Aug; 57(15):2147-2156. PubMed ID: 29607968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
    Scheen AJ
    Diabetes Metab; 2020 Jun; 46(3):186-196. PubMed ID: 32007623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.